Clinical Trial Update: A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China [Phase 3]

View source ↗

Summary

Phase 3 trial assessing lenvatinib (E7080) in radioiodine-refractory differentiated thyroid cancer conducted in China has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Differentiated Thyroid Cancer (DTC) | Phase 3 | Status: COMPLETED